Curated News
By: NewsRamp Editorial Staff
June 10, 2025
Oragenics to Showcase Concussion Treatment at Major Biotech Events
TLDR
- Oragenics showcases ONP-002 at BIO International Convention, offering investors a glimpse into its potential lead in concussion treatment innovation.
- Oragenics' Greg Gironda presents ONP-002, an intranasal neurosteroid for concussion, at key neuroscience and pharmaceutical events to engage with sector leaders.
- Oragenics' ONP-002 development represents a hopeful advance in concussion treatment, aiming to improve recovery outcomes for patients worldwide.
- Discover Oragenics' ONP-002, a novel intranasal treatment for concussions, at the forefront of neuroscience innovation this June in Boston and Philadelphia.
Impact - Why it Matters
This news is significant as it highlights Oragenics' commitment to advancing treatment options for concussions and other neurological conditions. With concussions being a major concern in sports and everyday accidents, the development of effective treatments like ONP-002 could have a profound impact on patient recovery and quality of life. Additionally, Oragenics' participation in these prestigious events underscores the potential of their research to attract attention and investment from the global biotech community, accelerating the path to market for their innovative therapies.
Summary
Oragenics (NYSE American: OGEN), a development-stage biotechnology company, is set to make waves at two major upcoming events: the 2025 BIO International Convention in Boston and the 42nd Annual National Neurotrauma Society Symposium in Philadelphia. Greg Gironda, the company's Head of Business Development, will present at the BIO International Convention, highlighting ONP-002, Oragenics' innovative intranasal neurosteroid candidate aimed at treating concussions. These events serve as pivotal opportunities for Oragenics to showcase its advancements in neurology and infectious disease treatments, including its work on mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC), to a global audience of industry leaders and researchers.
For those interested in learning more about Oragenics and its groundbreaking work, the company's website and the latest updates on OGEN offer a wealth of information. Additionally, the press release detailing these upcoming presentations can be found through the provided link, offering a deeper dive into Oragenics' contributions to the biotechnology field.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics to Showcase Concussion Treatment at Major Biotech Events
